178 related articles for article (PubMed ID: 30850497)
1.
Yoshii Y; Matsumoto H; Yoshimoto M; Oe Y; Zhang MR; Nagatsu K; Sugyo A; Tsuji AB; Higashi T
J Nucl Med; 2019 Oct; 60(10):1437-1443. PubMed ID: 30850497
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of vorinostat-sensitized intraperitoneal radioimmunotherapy with
Tachibana T; Yoshii Y; Matsumoto H; Zhang MR; Nagatsu K; Hihara F; Igarashi C; Sugyo A; Tsuji AB; Higashi T
J Cancer Res Ther; 2022; 18(4):907-914. PubMed ID: 36149139
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized
Hihara F; Matsumoto H; Yoshimoto M; Masuko T; Endo Y; Igarashi C; Tachibana T; Shinada M; Zhang MR; Kurosawa G; Sugyo A; Tsuji AB; Higashi T; Kurihara H; Ueno M; Yoshii Y
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628616
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [
Boyle AJ; Cao PJ; Cai Z; Chan C; Hedley DW; Reilly RM
Nucl Med Biol; 2020; 84-85():46-54. PubMed ID: 32062317
[TBL] [Abstract][Full Text] [Related]
5. Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with
Yoshii Y; Yoshimoto M; Matsumoto H; Tashima H; Iwao Y; Takuwa H; Yoshida E; Wakizaka H; Yamaya T; Zhang MR; Sugyo A; Hanadate S; Tsuji AB; Higashi T
Oncotarget; 2018 Jun; 9(48):28935-28950. PubMed ID: 29989003
[TBL] [Abstract][Full Text] [Related]
6. Immuno-OpenPET: a novel approach for early diagnosis and image-guided surgery for small resectable pancreatic cancer.
Yoshii Y; Tashima H; Iwao Y; Yoshida E; Wakizaka H; Akamatsu G; Yamaya T; Matsumoto H; Yoshimoto M; Igarashi C; Hihara F; Tachibana T; Zhang MR; Nagatsu K; Sugyo A; Tsuji AB; Higashi T
Sci Rep; 2020 Mar; 10(1):4143. PubMed ID: 32157106
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.
Milenic DE; Baidoo KE; Kim YS; Brechbiel MW
MAbs; 2015; 7(1):255-64. PubMed ID: 25587678
[TBL] [Abstract][Full Text] [Related]
8. Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells.
Gürlevik E; Fleischmann-Mundt B; Brooks J; Demir IE; Steiger K; Ribback S; Yevsa T; Woller N; Kloos A; Ostroumov D; Armbrecht N; Manns MP; Dombrowski F; Saborowski M; Kleine M; Wirth TC; Oettle H; Ceyhan GO; Esposito I; Calvisi DF; Kubicka S; Kühnel F
Gastroenterology; 2016 Aug; 151(2):338-350.e7. PubMed ID: 27210037
[TBL] [Abstract][Full Text] [Related]
9. Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.
Gold DV; Schutsky K; Modrak D; Cardillo TM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3929S-37S. PubMed ID: 14506191
[TBL] [Abstract][Full Text] [Related]
10. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
[TBL] [Abstract][Full Text] [Related]
11. Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with
Sugyo A; Tsuji AB; Sudo H; Koizumi M; Ukai Y; Kurosawa G; Kurosawa Y; Saga T; Higashi T
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274301
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
[TBL] [Abstract][Full Text] [Related]
13. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine.
Karacay H; Sharkey RM; Gold DV; Ragland DR; McBride WJ; Rossi EA; Chang CH; Goldenberg DM
J Nucl Med; 2009 Dec; 50(12):2008-16. PubMed ID: 19949026
[TBL] [Abstract][Full Text] [Related]
14. The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer.
Guo Y; Parry JJ; Laforest R; Rogers BE; Anderson CJ
J Nucl Med; 2013 Sep; 54(9):1621-9. PubMed ID: 23873478
[TBL] [Abstract][Full Text] [Related]
15. Significant Therapeutic Efficacy with Combined Radioimmunotherapy and Cetuximab in Preclinical Models of Colorectal Cancer.
Vassileva V; Rajkumar V; Mazzantini M; Robson M; Badar A; Sharma S; Årstad E; Hochhauser D; Lythgoe MF; Kinghorn J; Boxer GM; Pedley RB
J Nucl Med; 2015 Aug; 56(8):1239-45. PubMed ID: 26045312
[TBL] [Abstract][Full Text] [Related]
16. Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer.
Cardillo TM; Blumenthal R; Ying Z; Gold DV
Int J Cancer; 2002 Jan; 97(3):386-92. PubMed ID: 11774294
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model.
Tepel J; Kruse ML; Kapischke M; Haye S; Sipos B; Kremer B; Kalthoff H
Pancreatology; 2006; 6(3):240-7. PubMed ID: 16543775
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.
Buchsbaum DJ; Bonner JA; Grizzle WE; Stackhouse MA; Carpenter M; Hicklin DJ; Bohlen P; Raisch KP
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1180-93. PubMed ID: 12419447
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal radioimmunotherapy to treat the early phase of peritoneal dissemination of human colon cancer cells in a murine model.
Kinuya S; Yokoyama K; Fukuoka M; Hiramatsu T; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
Nucl Med Commun; 2007 Feb; 28(2):129-33. PubMed ID: 17198354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
